Protagenic Therapeutics, Inc.\new Finite-Lived Intangible Assets, Net
Protagenic Therapeutics, Inc.\new (PTIX) had Finite-Lived Intangible Assets, Net of $2.08 million as of 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent › Intangible Asset, Excluding Goodwill, after Accumulated Amortization
us-gaap:FiniteLivedIntangibleAssetsNet · last filed 2026-08-19
- 2026-06-30: Finite-Lived Intangible Assets, Net $2.08M.
- 2026-03-31: Finite-Lived Intangible Assets, Net $2.09M.
- 2025-12-31: Finite-Lived Intangible Assets, Net $2.09M.
- 2025-09-30: Finite-Lived Intangible Assets, Net $2.09M.
| Period end | Finite-Lived Intangible Assets, Net |
|---|---|
| 2026-06-30 | $2.08M 10-Q · filed 2026-08-19 |
| 2026-03-31 | $2.09M 10-Q · filed 2026-08-19 |
| 2025-12-31 | $2.09M 10-Q · filed 2026-03-09 |
| 2025-09-30 | $2.09M 10-Q · filed 2025-11-26 |
| 2025-06-30 | $2.09M 10-QT · filed 2025-09-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |